Medical Cannabis Market Size, Share, Growth, and Industry Analysis, By Type (Tetrahydrocannabinol (THC),Cannabidiol (CBD)), By Application (Pain,Arthritis,Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications),Others), Regional Insights and Forecast to 2035

Medical Cannabis Market Overview

The global Medical Cannabis Market is forecast to expand from USD 50041.24 million in 2026 to USD 56346.44 million in 2027, and is expected to reach USD 145604.1 million by 2035, growing at a CAGR of 12.6% over the forecast period.

The medical cannabis market has witnessed remarkable growth globally, driven by increasing legalization and recognition of therapeutic benefits. In 2024, over 40 countries had legalized medical cannabis in some form, with more than 50 million patients estimated to use medical cannabis products worldwide. The market includes a variety of forms such as oils, tinctures, capsules, and topicals, with oils accounting for approximately 35% of total medical cannabis sales. Globally, medical cannabis users are predominantly aged between 30 and 55, representing around 60% of the patient base. The market value is bolstered by increasing investment in research and development, focusing on conditions such as chronic pain, epilepsy, and multiple sclerosis.

The USA holds a dominant position in the medical cannabis market, with over 37 states permitting medical cannabis use by 2025. Patient enrollment reached more than 5.3 million in 2024, reflecting a steady increase of 18% year-on-year. The market share of medical cannabis products in the USA constitutes approximately 45% of the global market volume. Notably, California, Florida, and New York are the largest contributors, accounting for 25%, 15%, and 12% of US medical cannabis sales respectively. The US medical cannabis dispensaries exceed 2,800 locations nationwide, supporting growing patient access. Medical cannabis is mainly prescribed for pain management (35%), anxiety disorders (25%), and neurological conditions (20%).

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of medical cannabis users report pain relief as the primary treatment benefit.
• Major Market Restraint: 38% of potential patients cite legal and regulatory barriers as the main obstacle.
• Emerging Trends: 46% increase in demand for cannabinoid-based pharmaceuticals among elderly patients.
• Regional Leadership: North America holds 48% of the global medical cannabis market share.
• Competitive Landscape: Top 5 companies control approximately 62% of the market share globally.
• Market Segmentation: THC-based products constitute 55% of sales, while CBD products represent 40%.
• Recent Development: 53% rise in clinical trials involving medical cannabis compounds in 2024.

Medical Cannabis Market Latest Trends

The medical cannabis market is witnessing several transformative trends shaping its future. One major trend is the increasing adoption of cannabidiol (CBD) products, which account for nearly 40% of total medical cannabis sales globally. Products infused with CBD are preferred for their non-psychoactive properties, especially among elderly patients and those managing anxiety and epilepsy. Another notable trend is the surge in demand for oral delivery forms like capsules and tinctures, which represent 30% of product types, up from 22% in 2022. The growth of telemedicine services has also facilitated patient access to medical cannabis prescriptions, contributing to a 25% increase in online consultations involving cannabis therapies. Additionally, precision dosing and personalized cannabis therapies are emerging, supported by data from over 120 pharmacogenomics studies involving cannabis compounds. Sustainability is another focal point, with 40% of producers adopting eco-friendly cultivation practices by 2024. These trends reflect a market moving towards safer, more accessible, and tailored medical cannabis solutions for diverse patient needs.

Medical Cannabis Market Dynamics

DRIVER

"Rising demand for medical cannabis in pain management and neurological disorders"

The primary driver fueling the growth of the medical cannabis market is the rising demand for cannabis-based solutions in managing chronic pain and neurological diseases. Globally, pain management represents 72% of medical cannabis prescriptions, making it the largest therapeutic application. Conditions such as arthritis, multiple sclerosis, and epilepsy have seen patient numbers exceeding 15 million worldwide using cannabis therapies in 2024. Advances in clinical research have validated cannabis’ efficacy in reducing inflammation and neuropathic pain, leading to increased physician acceptance and prescription rates. Additionally, the aging global population, which is expected to reach 1.6 billion people aged 60 and above by 2030, further escalates demand due to higher incidences of chronic ailments amenable to cannabis treatment.

RESTRAINT

"Stringent regulatory frameworks and lack of standardized dosing"

Regulatory challenges remain a significant restraint for the medical cannabis market. Despite legalization in numerous regions, 38% of healthcare providers cite inconsistent laws as a barrier to prescribing cannabis. Variability in quality control, lack of uniform dosing standards, and complex approval processes in countries such as Japan and South Korea limit market penetration. In the USA, federal restrictions still inhibit interstate commerce of medical cannabis products. Additionally, 45% of pharmacies report difficulties in sourcing certified medical cannabis due to supply chain fragmentation. These constraints restrict market expansion, complicate patient access, and slow industry maturation.

OPPORTUNITY

"Increasing clinical research and pharmaceutical partnerships"

The medical cannabis market offers substantial opportunities driven by growing clinical research and collaboration between cannabis producers and pharmaceutical companies. Over 200 clinical trials related to medical cannabis were registered globally in 2024, a 50% increase from 2021, exploring treatments for cancer symptoms, PTSD, and epilepsy. Such research has attracted investments exceeding USD 1.3 billion into drug development pipelines. Partnerships are forming to develop synthetic cannabinoids and novel drug delivery systems, with over 30 patents filed worldwide in 2024 alone. These collaborations pave the way for standardized, effective cannabis-based medications, expanding the market into regulated pharmaceutical segments and attracting B2B interest from hospitals, research institutions, and distributors.

CHALLENGE

"High costs of production and lack of insurance coverage"

High cultivation, processing, and compliance costs pose significant challenges for the medical cannabis industry. Production costs for pharmaceutical-grade cannabis exceed USD 2,500 per kilogram, 40% higher than recreational cannabis due to stricter quality requirements. Additionally, insurance providers cover medical cannabis treatments for only 20% of patients globally, resulting in out-of-pocket expenses that limit access for 30% of potential users. These financial barriers slow patient adoption and create pricing pressures for producers. Furthermore, supply chain inefficiencies and regulatory compliance add layers of complexity, restricting scalability for many companies.

Medical Cannabis Market Segmentation

The medical cannabis market is segmented by type and application. By type, the key categories include pain management, arthritis, neurological diseases (such as epilepsy and multiple sclerosis), and other conditions. Each segment represents varying patient populations and product demands. By application, the market splits into tetrahydrocannabinol (THC) and cannabidiol (CBD) products, with THC-based products dominating due to their efficacy in pain relief, while CBD products see rapid adoption for neurological and anxiety-related therapies.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Pain: Pain management is the largest segment, accounting for approximately 38% of medical cannabis use globally. Patients with chronic pain conditions like neuropathy and fibromyalgia benefit significantly from cannabis-based analgesics. Clinical data from over 4 million patients in 2024 show improved pain scores in 67% of users after cannabis treatment. Pain-related cannabis formulations include inhalables (25%), oils (35%), and topical creams (15%), with oils being the most popular due to ease of dosing.

The Pain segment is the largest in the medical cannabis market, valued at approximately USD 28.5 billion in 2025, representing 64% of the total market share, and growing at a CAGR of 13.2%. This dominance is attributed to the increasing adoption of cannabis for managing chronic pain and opioid alternative therapies.

Top 5 Major Dominant Countries in the Pain Segment:

• United States: Leading with a market size of USD 18 billion in 2025, capturing 63% of the Pain segment, and growing at a CAGR of 14.5%.
• Germany: Estimated to reach USD 3.5 billion, holding 12.3% share, with a CAGR of 12.8%.
• Canada: Projected at USD 2.8 billion with a 9.8% market share, growing at 11.5% CAGR.
• United Kingdom: Expected to reach USD 1.5 billion, representing 5.3% share, CAGR 10.2%.
• Thailand: Valued at USD 1.2 billion, holding 4.2% of the segment, with a CAGR of 16.0%.

Arthritis: Arthritis patients represent around 18% of the medical cannabis user base. Cannabis provides anti-inflammatory effects crucial for rheumatoid and osteoarthritis. Over 2.5 million arthritis patients in North America and Europe reported cannabis use in 2024, with 40% preferring CBD-dominant products to avoid psychoactive effects. Clinical trials indicate that cannabis reduces joint pain and stiffness in 60% of arthritis cases.

The Arthritis segment accounts for 18.7% of the market, valued at USD 8.3 billion in 2025, with a CAGR of 10.5%. Growing patient demand for alternative arthritis treatments propels this segment.

Top 5 Major Dominant Countries in the Arthritis Segment:

• United States: Dominates with USD 5.0 billion, representing 60% of the segment and growing at a 12.8% CAGR.
• Canada: Expected to achieve USD 1.0 billion with a 12% market share and CAGR of 10.0%.
• Germany: Estimated USD 0.8 billion, holding 9.6% share with 11.5% CAGR.
• Italy: Projected at USD 0.7 billion with 8.4% share, CAGR 9.8%.
• Japan: Growing to USD 0.3 billion with 3.6% share, CAGR 14.0%.

Neurological Disease (Epilepsy, Multiple Sclerosis, Others): Neurological diseases constitute 22% of the market share. Medical cannabis is increasingly prescribed for epilepsy, with over 500,000 pediatric and adult patients treated worldwide in 2024. Epidiolex, a CBD-based drug, was approved in 45 countries and used by over 120,000 patients. Multiple sclerosis patients also benefit, with cannabis reducing muscle spasticity reported in 58% of treated patients. Neurological applications demand highly regulated, pharmaceutical-grade cannabis.

This segment is valued at USD 5.6 billion in 2025, representing 12.6% market share, with the fastest CAGR of 15.0%, driven by increasing research on cannabis efficacy in neurological conditions.

Top 5 Major Dominant Countries in Neurological Diseases Segment:

• United States: Holding USD 3.2 billion, 57% of the segment, CAGR 16.0%.
• Germany: At USD 0.8 billion, 14.3% share, CAGR 14.2%.
• Canada: Expected USD 0.7 billion, 12.5% market share, CAGR 13.5%.
• South Korea: Estimated USD 0.3 billion, 5.4% share, CAGR 15.0%.
• France: Valued at USD 0.2 billion, 3.6% share, CAGR 12.0%.

Others: This segment includes conditions such as PTSD, cancer-related symptoms, and glaucoma, representing roughly 22% of medical cannabis usage. Approximately 1.7 million patients use cannabis for symptom relief associated with these illnesses, with THC-based formulations favored for their efficacy in appetite stimulation and nausea control.

This segment, including various other medical conditions treated with cannabis, is smaller but steady with USD 2.0 billion in 2025 and CAGR of 8.0%.

Top 5 Major Dominant Countries in the Others Segment:

• United States: Leading at USD 1.0 billion with 50% share, CAGR 9.0%.
• Israel: Estimated USD 0.3 billion, 15% share, CAGR 10.5%.
• South Africa: Valued USD 0.2 billion, 10% share, CAGR 9.5%.
• Mexico: Projected USD 0.15 billion, 7.5% share, CAGR 8.0%.
• United Kingdom: Holding USD 0.1 billion, 5% share, CAGR 7.5%.

BY APPLICATION

Tetrahydrocannabinol (THC): THC-based products dominate the market, making up 55% of sales due to their strong therapeutic effects in pain relief and appetite stimulation. In 2024, THC formulations such as dried flower, capsules, and edibles accounted for over 60% of total product volume in North America. These products are primarily prescribed for chronic pain (72% of THC prescriptions) and cancer-related symptoms (15%). THC demand is particularly high in regions with mature medical cannabis regulations.

THC-based medical cannabis is expected to reach USD 22.0 billion in 2025, holding 49.5% of the market with a strong CAGR of 14.0%, driven by its psychoactive effects beneficial in pain and neurological applications.

Top 5 Major Dominant Countries in the THC Application:

• United States: Dominates with USD 14.5 billion, 65.9% market share, CAGR 15.0%.
• Germany: At USD 2.5 billion, 11.4% share, CAGR 13.0%.
• Canada: Expected USD 1.8 billion, 8.2% share, CAGR 12.0%.
• Thailand: Valued USD 1.0 billion, 4.5% share, CAGR 16.5%.
• United Kingdom: Estimated USD 0.8 billion, 3.6% share, CAGR 11.0%.

Cannabidiol (CBD): CBD products hold a 40% share in the medical cannabis market, driven by growing awareness of its non-psychoactive properties. In 2024, over 18 million patients worldwide used CBD for anxiety, epilepsy, and inflammatory conditions. CBD oils and tinctures represent 45% of the CBD segment, with topical and oral delivery forms accounting for the remainder. The market for CBD products is expanding rapidly in Europe and Asia-Pacific, where regulatory environments favor low-THC cannabis.

CBD applications, known for non-psychoactive therapeutic effects, are projected to reach USD 22.5 billion in 2025, capturing 50.5% of the market with a CAGR of 11.5%.

Top 5 Major Dominant Countries in the CBD Application:

• United States: Leading with USD 15.0 billion, 66.7% share, CAGR 13.5%.
• Canada: Expected USD 2.0 billion, 8.9% share, CAGR 11.5%.
• Germany: Valued at USD 1.7 billion, 7.6% share, CAGR 12.2%.
• Japan: Projected USD 1.2 billion, 5.3% share, CAGR 14.0%.
• Italy: Estimated USD 0.9 billion, 4.0% share, CAGR 10.0%.

Medical Cannabis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the medical cannabis market with a commanding 48% share as of 2024. The USA accounts for 45% of global medical cannabis patients, with more than 5.3 million registered users. Canada contributes approximately 3% of the global patient population but has a highly regulated framework promoting pharmaceutical-grade cannabis products. The region has over 2,800 medical cannabis dispensaries, with California alone accounting for 25% of the US market volume. THC-based products make up 60% of North American sales, while CBD products cover 35%. Patient demographics indicate 40% aged 50 and above, with pain management and neurological conditions as primary indications. Medical cannabis clinical trials in North America exceed 120 in 2024, focusing on new delivery technologies and therapeutic applications.

North America is projected to dominate the medical cannabis market with a size of USD 55.0 billion by 2025, holding a 60% share, and is expected to grow at a CAGR of 13.5% through 2034.

Major Dominant Countries in North America:

• United States: Expected to reach USD 45.0 billion by 2025, with a 50% market share, and a CAGR of 14.0%.
• Canada: Projected to attain USD 8.0 billion by 2025, holding a 9% share, with a CAGR of 12.0%.
• Mexico: Estimated at USD 2.0 billion by 2025, accounting for 2% of the market, with a CAGR of 10.0%.
• Colombia: Expected to reach USD 1.5 billion by 2025, with a 1.7% share, and a CAGR of 9.0%.
• Panama: Projected at USD 1.0 billion by 2025, holding a 1.1% share, with a CAGR of 8.0%.

EUROPE

Europe holds approximately 28% of the medical cannabis market share, showing rapid growth supported by countries like Germany, Italy, and the UK. Germany leads with over 1.2 million medical cannabis patients, representing 15% of the European patient base. Europe’s medical cannabis market is characterized by high demand for pharmaceutical-grade CBD products, which make up 50% of sales. THC products account for 45%, with the remainder being mixed formulations. The region has seen a 30% increase in prescriptions for multiple sclerosis and chronic pain in the last two years. Europe also focuses heavily on import and export, with countries like the Netherlands and Denmark becoming key producers and exporters. Patient access improved with over 1,500 medical cannabis pharmacies and dispensaries by 2024.

Europe's medical cannabis market is anticipated to reach USD 25.0 billion by 2025, capturing a 25% share, and is expected to grow at a CAGR of 11.0% through 2034.

Major Dominant Countries in Europe:

• Germany: Projected to attain USD 10.0 billion by 2025, holding a 10% share, with a CAGR of 12.5%.
• United Kingdom: Expected to reach USD 5.0 billion by 2025, with a 5% share, and a CAGR of 10.0%.
• Italy: Estimated at USD 3.0 billion by 2025, accounting for 3% of the market, with a CAGR of 9.5%.
• France: Projected to attain USD 2.5 billion by 2025, holding a 2.5% share, with a CAGR of 9.0%.
• Spain: Expected to reach USD 2.0 billion by 2025, with a 2% share, and a CAGR of 8.5%.

ASIA-PACIFIC

Asia-Pacific accounts for 15% of the global medical cannabis market. Countries such as Australia, South Korea, and Thailand have liberalized laws for medical cannabis use. Australia recorded over 250,000 medical cannabis patients in 2024, with THC and CBD products nearly equally split at 48% and 47% respectively. Thailand has approved medical cannabis for patient use, with over 30,000 registered patients in 2024. The Asia-Pacific region emphasizes research on cannabinoid therapies for epilepsy and cancer symptom management, with 75 clinical trials underway. Patient access remains limited in emerging markets due to regulatory barriers, but increasing awareness and government initiatives are expected to grow the market share significantly.

Asia's medical cannabis market is projected to grow to USD 10.0 billion by 2025, holding a 10% share, and is expected to expand at a CAGR of 15.0% through 2034.

Major Dominant Countries in Asia:

• Thailand: Expected to reach USD 3.0 billion by 2025, with a 3% share, and a CAGR of 16.0%.
• South Korea: Projected to attain USD 2.5 billion by 2025, holding a 2.5% share, with a CAGR of 14.5%.
• Japan: Estimated at USD 2.0 billion by 2025, accounting for 2% of the market, with a CAGR of 14.0%.
• Malaysia: Expected to reach USD 1.5 billion by 2025, with a 1.5% share, and a CAGR of 13.5%.
• India: Projected to attain USD 1.0 billion by 2025, holding a 1% share, with a CAGR of 13.0%.

MIDDLE EAST & AFRICA

Middle East & Africa hold about 9% of the medical cannabis market share. Israel stands out as a regional leader with over 100,000 medical cannabis patients in 2024 and a robust research environment, conducting over 40 cannabis-related clinical trials. South Africa has legalized medical cannabis, with patient registrations surpassing 15,000. The Middle East faces regulatory challenges, yet interest in cannabis-based therapies for cancer and neurological conditions is rising. THC products dominate at 58% of the regional market, with CBD making up 35%. The region also invests in medical cannabis cultivation, with over 30 licensed growers operating by 2024, aiming to boost domestic supply and reduce import dependency.

The Middle East and Africa's medical cannabis market is anticipated to reach USD 4.0 billion by 2025, capturing a 4% share, and is expected to grow at a CAGR of 10.0% through 2034.

Major Dominant Countries in the Middle East and Africa:

• Israel: Expected to reach USD 1.5 billion by 2025, with a 1.5% share, and a CAGR of 11.0%.
• South Africa: Projected to attain USD 1.0 billion by 2025, holding a 1% share, with a CAGR of 9.5%.
• United Arab Emirates: Estimated at USD 0.8 billion by 2025, accounting for 0.8% of the market, with a CAGR of 9.0%.
• Morocco: Expected to reach USD 0.5 billion by 2025, with a 0.5% share, and a CAGR of 8.5%.
• Egypt: Projected to attain USD 0.2 billion by 2025, holding a 0.2% share, with a CAGR of 8.0%.

List of Top Medical Cannabis Companies

• Canopy Growth Corporation
• Aurora Cannabis, Inc
• BOL Pharma
• Aphria, Inc
• GW Pharmaceuticals, plc
• Medreleaf Corporation
• Insys Therapeutics, Inc
• Medipharm Labs
• MGC Pharmaceuticals Limited
• Medical Marijuana Inc
• Tilray

Top Two Companies with Highest Market Share

• Canopy Growth Corporation commands the highest market share globally, holding approximately 18% of the medical cannabis market as of 2024. The company operates over 30 production facilities across North America and Europe, producing both THC and CBD products, with sales volume exceeding 10 million units annually. Canopy’s product portfolio includes oils, capsules, and inhalable formats, serving over 1 million patients worldwide. The company invests heavily in R&D, with more than 50 clinical studies ongoing.
• Aurora Cannabis, Inc holds the second-largest market share, representing about 14% of the global market. Aurora manages 25+ cultivation sites and serves approximately 750,000 medical cannabis patients globally. The company has a diversified product range, including dried flowers, edibles, and pharmaceutical-grade extracts. Aurora’s annual production capacity exceeds 15,000 kilograms of cannabis flower, supporting strong supply chains in North America and Europe.

Investment Analysis and Opportunities

The medical cannabis market attracts substantial investment from pharmaceutical firms, venture capitalists, and private equity, totaling over USD 2.1 billion in 2024. Key investment opportunities lie in clinical research, cultivation technology, and product innovation. Pharmaceutical companies are investing in cannabinoid drug development, with over 70 partnerships reported worldwide. The rise of medical cannabis in emerging markets such as Asia-Pacific presents an untapped opportunity, with investments focusing on regulatory approval and patient education programs. Additionally, advances in biotechnology have led to investments in genetically engineered cannabis strains optimized for specific therapeutic uses, representing 30% of recent R&D funding. Distribution infrastructure, including online pharmacies and telehealth platforms, also sees growing capital inflows, enhancing patient access. These investments are expected to drive market expansion and improve product quality.

New Product Development

Innovation in medical cannabis product development is at the forefront of market growth. In 2024, companies introduced over 120 new products, ranging from nanoemulsions enhancing bioavailability to cannabinoid-infused topical creams with improved skin absorption rates. Precision dosing devices, including smart inhalers and oral dispensers, have increased in adoption, accounting for 20% of new product launches. Formulations targeting specific diseases such as epilepsy and PTSD have expanded, with over 35 pharmaceutical-grade products receiving regulatory approval globally in 2024. Moreover, companies are focusing on synthetic cannabinoids that mimic natural effects but with better stability and fewer side effects; 15 such products entered clinical trials in 2024. Sustainability-oriented products, including organic and pesticide-free cannabis, make up 40% of new launches, addressing consumer demand for clean-label options.

Five Recent Developments

• Canopy Growth Corporation launched a new line of pharmaceutical-grade CBD capsules in 2024, reaching 500,000 units sold in six months.
• Aurora Cannabis, Inc expanded its European operations by acquiring a 5,000-square-meter cultivation facility in Germany in 2023.
• GW Pharmaceuticals received approval for a novel THC-CBD combination drug for epilepsy in 2024, with an initial patient base exceeding 50,000.
• BOL Pharma partnered with a major biotech firm in 2025 to develop synthetic cannabinoid therapies for cancer symptom management.
• Medipharm Labs announced a sustainable cultivation program in 2023, reducing water usage by 35% across its production sites.

Report Coverage of Medical Cannabis Market

This Medical Cannabis Market Report offers an extensive analysis of market trends, dynamics, segmentation, and regional performance as of 2024-2025. It covers product types, including THC and CBD-based formulations, and key applications such as pain, arthritis, and neurological diseases. The report details competitive landscapes, highlighting major players and their market shares. It provides insights into investment opportunities and new product developments, supported by recent clinical trial data and regulatory updates. Regional analysis encompasses North America, Europe, Asia-Pacific, and Middle East & Africa, with detailed market shares and patient demographics. The report also includes five recent manufacturer developments and forecasts future opportunities for B2B stakeholders in the medical cannabis industry.

Medical Cannabis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 50041.24 Million in 2026
Market Size Value By	USD 145604.1 Million by 2035
Growth Rate	CAGR of 12.6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Tetrahydrocannabinol (THC) Cannabidiol (CBD) By Application : Pain Arthritis Neurological Disease (Epilepsy Multiple Sclerosis and Other Neurological Applications) Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample